
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Therapeutic Management of Immune Thrombocytopenia
Case: A 48-year-old woman presenting with unusual bruising
October 2017
April 2018
